Background: The mucositis of anti-epidermal growth factor receptor monoclonal antibodies was poorly understood. We conducted this systematic review to fully investigate the mucositis of antiepidermal growth factor receptor monoclonal antibodies in cancer patients. Study design: EMBASE, MEDLINE and PubMed were searched for articles published till December 2017. The relevant randomized controlled trials in cancer patients treated with anti-epidermal growth factor receptor monoclonal antibodies were retrieved and the systematic evaluation was conducted. Results: Thirty-six randomized controlled trials and 15,364 patients were included. The current meta-analysis suggests that the use of anti-epidermal growth factor receptor monoclonal antibodies significantly increases the risk of developing all-grade (RR, 1.48; 95% CI, 1.24-1.77; P < 0.0001) and high-grade mucositis (RR, 2.16; 95% CI, 1.61-2.89; P < 0.00001). The relative risk of high-grade mucositis tended to be higher in colorectal cancer patients than non-colorectal cancer patients. Conclusions: The available data suggested that the use of anti-epidermal growth factor receptor monoclonal antibodies significantly increases the risk of developing mucositis. Physicians should be aware of mucositis and should monitor cancer patients when receiving anti-epidermal growth factor receptor monoclonal antibodies.
Introduction
The epidermal growth factor receptor (EGFR) is a member of the HER family of receptor tyrosine kinases that regulates key cellular functions in epithelial malignancies (1) . EGFR and its family members play an important role in proliferation, antiapoptosis, differentiation, adhesion, migration and survival of cancer cells (2) . Currently, several anti-EGFR agents, including monoclonal antibodies (MoAbs) and small-molecule tyrosine kinase inhibitors, have been approved for use in the therapy of a range of solid tumors including those of the colorectal cancer (CRC), head and neck carcinoma and non-small-cell lung cancer (NSCLC).
Anti-epidermal growth factor receptor monoclonal antibodies (EGFR-MoAbs), such as cetuximab, panitumumab and nimotuzumab, are relatively well tolerated and lack the typical adverse events of cytotoxic chemotherapy, have been associated with increased incidence of several specific drug-related toxicities, including skin toxicity, gastrointestinal reactions, hematological disorders and infusion reactions (3) . Mucositis is a common adverse events associated with anti-EGFR therapy. Mucositis is commonly mild or moderate but may be sometimes severe, which can affect the quality of life (QOL) and results in undesirable dose reduction or discontinuation. Moreover, prolonged or profound oral and gastrointestinal mucositis can lead to painful ulcerations, bleeding, infections, dysphagia, bloatedness and diarrhea (4) . It is necessary to shed more light on this common side effect. However, the risk of mucositis in cancer patients treated with EGFR-MoAbs varies widely across clinical trials, and risk factors underlying the variation are still unclear. Therefore, we conducted this meta-analysis of 36 randomized controlled trials (RCTs) to fully investigate the mucositis of EGFRMoAbs in patients with cancer.
Patients and methods

Search strategy and study selection
Study was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement (5) . An independent review of citations from EMBASE from 1 January 1974 to 31 December 2017 was conducted.
Databases were searched using combinations of the following keywords 'cetuximab', 'panitumumab', 'nimotuzumab', 'imgatuzumab', 'tumor' and 'cancer'. The search was limited to R×CTs published in English. We also performed independent searches using PubMed/Medline between 1 January 1966 and 31 December 2017 to ensure that no clinical trials were overlooked. At each screening level, investigators of the review team selected articles for inclusion independently after an initial calibration exercise. RCTs met the following criteria were (i) participants assigned to treatment with one of these agents (cetuximab, panitumumab, nimotuzumab and imgatuzumab), (ii) randomized controlled phase II and III trials in patients with cancer and (iii) events or event rate and sample size available for mucositis or stomatitis. EGFR-MoAbs in both treatment and control arms were excluded.
Data extraction
We extracted details on study characteristics, treatment information, results and safety profiles from selected studies. Mucositis was defined as per versions 2.0, 3.0 or 4.0 of the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) criteria. Data were extracted by one investigator and checked by another investigator. If a particular patient population was reported in more than one publication with the same outcome parameters, the article providing the most detailed data was included in the meta-analysis.
Quality assessment
Each study was independently assessed for quality and for potential bias by two reviewers (J.L. and J.X.) based on randomization procedure; blinding; allocation concealment; study withdrawals; comparability between groups at baseline and intention-to-treat (ITT) analyses. Two reviewers independently assessed each study for quality and risk of bias using the Jadad ranking system (6). Disagreements were resolved by consensus. 
Data analysis
RR of all-grade mucositis
All-grade mucositis occurred in 1650 of 4176 (39.5%) patients in the EGFR-MoAbs arms, and 1143 of 4102 (27.9%) in the placebo arms. A meta-analysis of the RR of all-grade mucositis was performed on the 25 RCTs (Fig. 2) . The RR of all-grade mucositis was 1.48 (95% CI, 1.24-1.77; P < 0.0001). Thus, patients treated with these agents had a significant increased risk of all-grade mucositis. Significant heterogeneity was detected among the studies (P < 0.00001, I 2 = 95%), which might be due to the different drug types, tumor types or line of therapy. Therefore, subgroup analyses were preformed according to these differences.
RR of high-grade mucositis
High-grade (≥grade 3) mucositis occurred in 547 of 7820 (7.0%) patients in the EGFR-MoAbs arms, and 282 of 7739 (3.6%) in the placebo arms. A meta-analysis of the RR of high-grade mucositis was performed on all the included RCTs (Fig. 3) . The RR of highgrade mucositis was 2.16 (95% CI, 1.61-2.89; P < 0.00001). Thus, patients treated with these agents had a significant increased risk of high-grade mucositis. Significant heterogeneity was found among the studies (P < 0.00001, I 2 = 65%), which might be due to the different drug types, tumor types or line of therapy, and subgroup analyses were preformed according to these differences.
Subgroup analyses
Subgroup analysis according to the agent used In order to explore the impact of individual agents on the RRs of mucositis, we calculated RRs according to the type of agent used. For all-grade mucositis, there was a significant difference in the RRs by type of drug (P < 0.0001, Table 2 ). No significant difference was observed in the RRs of high-grade mucositis by type of drug (P = 0.1, Table 3 ). Panitumumab was associated with the highest risk of all-grade mucositis (RR = 1.88), whereas nimotuzumab was not associated with significant increased risk of all-grade and high-grade mucositis.
Subgroup analysis according to the tumor types
In order to explore the relationship between EGFR-MoAbassociated mucositis and tumor types, we further analyzed the RRs of mucositis in patients with CRC and non-CRC. No significant difference was observed in the RRs of all-grade mucositis by type of tumor (P = 0.46, Table 2 ). For high-grade mucositis, there were significant differences in the RRs by the type of tumor (P < 0.0001, Table 3 ). All-grade mucositis were more likely to occur in patients with CRC (RR = 2.87) than with non-CRC (RR = 1.32).
Subgroup analysis according to treatment line
Studies were further stratified according to treatment line (first line or ≥second line). For both all-grade (P = 0.24, Table 2 ) and high-grade (P = 0.47, Table 3 ) mucositis, the differences in the RRs by line of therapy were not significant.
Subgroup analysis according to median treatment duration
Studies were further stratified according to median treatment duration (<5 months vs. ≥5 months, based on the EGFR-MoAbs arms). There was no significant difference in the RRs by the type of treatment duration for both all-grade (P = 0.57, Table 2 ) and high-grade mucositis (P = 0.17, Table 3 ).
Subgroup analysis according to median age
The differences in the RRs by median age (≤60 vs. >60, based on the EGFR-MoAbs arms) were not significant for both all-grade (P = 0.57, Table 2 ) and high-grade mucositis (P = 0.20, Table 3 ).
Publication bias
Funnel plots of the studies used in the meta-analysis to evaluate allgrade and high-grade mucositis are shown in Fig. 4 . No significant publication bias was found in the analysis.
Discussion
Mucositis is a common complication of cytoreductive cancer chemotherapy and radiotherapy. The pathogenesis of mucositis results from sequential steps starting from a cellular DNA direct damage, progressively amplified by inflammatory pathways, leads to ulceration and finally to the healing process. EGFR seems to play an important role in the healing process, because EGF and other CRC, colorectal cancer; NSCLC, non-small-cell lung cancer; SCC, squamous cell carcinoma; BTC, biliary tract cancer; NPC, nasopharyngeal carcinoma; NR, not reached; BEV, bevacizumab; PDD, cisplatin; CAP, capeticabine; PXT, paclitaxel; DXT, docetaxel; GEM, gemcitabine; BEV, bevacizumab; CBP, carboplation; mFOLFOX6, modified fluorouracil+leucovorin+irinotecan; FOLFIRI, irinotecan+fluorouracil+leucovorin; RT, radiotherapy; CRT, chemoradiotherapy; CAPOX, capecitabine+oxaliplatin; GEMOX, gemcitabine+oxaliplatin; FOLF, 5-fluorouracil+leucovorin; FLOX fluorouracil+folinic acid+oxaliplatin; EOC, epirubicin+oxaliplatin+capecitabine; wTCF, weekly docetaxel+cisplatin + fluoropyrimidine; EOC, epirubicin+oxaliplatin+capecitabine; XELOX, capecitabine+oxaliplatin.
growth factors can promote cell migration and increase blood flow, allowing repair of the denuded basal membrane (43) . Moreover, EGF may have a protective effect on gastrointestinal mucosa (44) . Therefore, the use of EGFR-MoAbs could inhibit both regenerative and protective effects, which would result in mucositis. It is now not considered a purely epithelial phenomenon but rather represents a complex interplay between all mucosal compartments. Furthermore, mucositis is now recognized to involve the entire alimentary tract not just the oral mucosa (45) . Mucositis induced by EGFR-MoAbs may negatively affect QOL and result in dose reduction or discontinuation. Moreover, it may increase mortality because of the increased risk of systemic infection. As EGFR-MoAbs were used increasingly in patients with various types of cancers, physicians should be aware of mucositis when using these drugs.
In our research, we found EGFR-MoAbs to be associated with a significantly increased risk of all-grade and high-grade mucositis. The incidence of all-grade and high-grade mucositis was 1.48 and 2.16 times more likely to occur in patients receiving EGFR-MoAbs versus control groups, respectively.
In order to identify potential risk factors, we performed subgroup analysis according to drug types, the risk of all-grade (P < 0.0001) mucositis varied significantly according to drug types. One possible explanation was that different EGFR-MoAbs target different receptors, which may lead to different risk of mucositis. Nimotuzumab tend to be associated with less all-grade mucositis than cetuximab and panitumumab, which may be due to nimotuzumab's unique EGFR-binding affinity and density selectivity. Moreover, nimotuzumab was reported to have less skin toxicities, such as rash, hand-foot skin reaction and dry skin. Nimotuzumab's benign side effect profile will make it an attractive therapeutic option when compared with other EGFR-MoAbs (46) . However, our analysis included only two RCTs about nimotuzumab, the above-mentioned result may due to analysis with a small sample size. Therefore, more RCTs about nimotuzumab should be included to strengthen this result. Patients with CRC had greater RR of highgrade mucositis than those with non-CRC. This could be due to the fact that intestinal system and epithelium have been damaged in CRC patients, and EGFR-MoAbs may aggravate the superficial necrosis and inflammation of the bowel wall. Therefore, there was higher risk of mucositis in CRC patients. Additionally, our subgroup analysis suggested that the RR of all-grade and high-grade mucositis did not vary significantly according to treatment line, treatment duration and patient's age.
A previous meta-analysis (47) evaluated the incidence of mucositis in CRC patients exposed to EGFR-MoAbs, however, it included only eight RCTs concerned about high-grade mucositis before 2015. The present meta-analysis included 36 RCTs about cetuximab and panitumumab and nimotuzumab. To the best of our knowledge, this is the largest and most comprehensive meta-analysis evaluating the risk of mucositis associated with EGFR-MoAbs.
Our meta-analysis has several limitations. First, the assessment of mucositis may vary among investigators and institutions that conducted these trials. The nosology of grading systems used by included trials, CTCAE versions 2.0, 3.0 and 4.0, are not specifically designed to reflect EGFR-associated mucositis, and subjective criteria may limit evaluation. Second, our study included a mixed population of patients treated with EGFR-MoAb-based combination (including FOLFOX, FOLFIRI, radiotherapy, paclitaxel, cisplatin, platinum and capecitabine) therapy or with EGFR-MoAbs alone. It is possible that the concomitant administration of other drugs may have contributed to a higher risk of mucositis. Patients who received placebo or non-placebo therapy were also included in our study. Therefore, the treatment design is not the same in all arms, which might increase heterogeneity. Also, the varying types of tumors and different EGFR-MoAbs examined might be another source of heterogeneity. Third, this is a meta-analysis at study level and not on the patients' data, the confounding factors at the patient level such as previous chemotherapeutic exposure and concomitant treatments cannot be assessed properly and incorporated into the analysis. In summary, our meta-analysis demonstrates that the use of EGFR-MoAbs significantly increase the risk of developing all-grade and high-grade mucositis. The risk of high-grade mucositis tended to be higher in CRC patients than non-CRC patients. Physicians should be aware of this adverse effect and should monitor cancer patients when receiving EGFR-MoAbs. Evidence-based guidelines on how to prevent or treat EGFR inhibitor-induced mucositis are needed for the management of EGFR-MoAb-induced mucositis.
Supplementary data
Supplementary data are available at Japanese Journal of Clinical Oncology online.
Funding
This work was supported by the Fundamental Research Funds for the Central Universities, Southwest Minzu University, 2018NQN50.
Conflict of interest statement
None declared.
Ethical approval
This article does not contain any studies with human participants or animals performed by any of the authors. 
